Exact Sciences (NASDAQ:EXAS – Free Report) had its target price decreased by Piper Sandler from $90.00 to $80.00 in a research note issued to investors on Monday, Benzinga reports. Piper Sandler currently has an overweight rating on the medical research company’s stock. A number of other research firms have also weighed in on EXAS. The […]
Private Trust Co. NA acquired a new stake in Exact Sciences Co. (NASDAQ:EXAS – Free Report) in the second quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund acquired 480 shares of the medical research company’s stock, valued at approximately $45,000. A number of other institutional investors and […]
EFG Asset Management North America Corp. lowered its position in Exact Sciences Co. (NASDAQ:EXAS – Free Report) by 9.6% in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 38,089 shares of the medical research company’s stock after selling […]
Operator: Good day and welcome to the Exact Sciences Second Quarter 2023 Earnings Call. Today s call is being recorded. All lines have been placed on mute to prevent any background noise.